Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Purpose: This two-stage phase IB study investigated the pharmacokinetics and safety of subcutaneous (SC) versus intravenous (IV) administration of rituximab as maintenance therapy in follicular lymphoma. Patients and Methods: In stage 1 (dose finding), 124 patients who responded to rituximab induction were randomly assigned to SC rituximab (375 mg/m 2 , 625 mg/m 2 , or an additional group at 800 mg/m 2 ) or IV rituximab (375 mg/m 2 ). The objective was to determine an SC dose that would yield a rituximab serum trough concentration (C trough ) in the same range as that of IV rituximab. In stage 2, 154 additional patients were randomly assigned (1:1) to SC rituximab (1,400 mg) or IV rituximab (375 mg/m 2 ) given at 2- or 3-month intervals. The objective was to demonstrate noninferior rituximab C trough of SC rituximab relative to IV rituximab 375 mg/m 2 . Results: Stage 1 data predicted that a fixed dose of 1,400 mg SC rituximab would result in a serum C trough in the range of that of IV rituximab. Noninferiority (ie, meeting the prespecified 90% CI lower limit of 0.8) was then confirmed in stage 2, with geometric mean C trough SC :C trough IV ratios for the 2- and 3-month regimens of 1.24 (90% CI, 1.02 to 1.51) and 1.12 (90% CI, 0.86 to 1.45), respectively. Overall safety profiles were similar between formulations (in stage 2, 79% of patients experienced one or more adverse events in each group). Local administration-related reactions (mainly mild to moderate) occurred more frequently after SC administration. Conclusion: The fixed dose of 1,400 mg SC rituximab predicted by using stage 1 results was confirmed to have noninferior C trough levels relative to IV rituximab 375 mg/m 2 dosing during maintenance, with a comparable safety profile. Additional investigation will be required to determine whether the SC route of administration for rituximab provides equivalent efficacy compared with that of IV administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Lundin, J., Kimby, E., Björkholm, M., Broliden, P.-A., Celsing, F., Hjalmar, V., Möllgård, L., Rebello, P., Hale, G., Waldmann, H., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0159 · Cited by 497
Ismael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S.-B., Pienkowski, T., Lichinitser, M., Semiglazov, V., Melichar, B., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70329-7 · Cited by 351 · cited 1×
“rHuPH20 temporarily cleaves hyaluronan fibers in the interstitial tissue, thereby facilitating the SC injection of large volumes, as demonstrated in other settings.(11-15) Switching from IV to SC administration may also improve adverse event (AE) profiles, increase patient convenience, and improve cost-effectiveness,…”
BackgroundFrost, G. I. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.4.427 · Cited by 323 · cited 1×
“rHuPH20 temporarily cleaves hyaluronan fibers in the interstitial tissue, thereby facilitating the SC injection of large volumes, as demonstrated in other settings.(11-15) Switching from IV to SC administration may also improve adverse event (AE) profiles, increase patient convenience, and improve cost-effectiveness,…”
Background
Cited by
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liu, L. (2018) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 390
Zhou, Q., Jin, J.-F., Zhu, L.-L., Chen, M., Xu, H.-M., Wang, H.-F., Feng, X.-Q., & Zhu, X.-P. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s87271 · Cited by 296
Rummel, M., Kim, T. M., Aversa, F., Brugger, W., Capochiani, E., Plenteda, C., Re, F., Trask, P., Osborne, S., Smith, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw685 · Cited by 154
Davies, A., Merli, F., Mihaljević, B., Mercadal, S., Siritanaratkul, N., Solal-Céligny, P., Boehnke, A., Berge, C., Genevray, M., Zharkov, A., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30078-9 · Cited by 125
Self-citationDe Cock, E., Kritikou, P., Sandoval, M., Tao, S., Wiesner, C., Carella, A. M., Ngoh, C., & Waterboer, T. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157957 · Cited by 108
Metadata
- Authors
- Salar, A., Avivi, I., Bittner, B., Bouabdallah, R., Brewster, M., Catalani, O., Follows, G., Haynes, A., Hourcade-Potelleret, F., Janikova, A., Larouche, J.-F., McIntyre, C., Pedersen, M., Pereira, J., Sayyed, P., Shpilberg, O., & Tumyan, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-06-10
- Volume
- 32
- Issue
- 17
- Pages
- 1782-1791
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2154839397
- Cited by
- 98
- References
- 4
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study. https://app.cochat.ai/papers/10.1200/jco.2013.52.2631
- The paper
- Salar, A., Avivi, I., Bittner, B., Bouabdallah, R., Brewster, M., Catalani, O., Follows, G., Haynes, A., Hourcade-Potelleret, F., Janikova, A., Larouche, J.-F., McIntyre, C., Pedersen, M., Pereira, J., Sayyed, P., Shpilberg, O., & Tumyan, G. (2014). Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2013.52.2631
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.